KR20240148351A - 브루톤 티로신 키나제 억제제의 합성 - Google Patents

브루톤 티로신 키나제 억제제의 합성 Download PDF

Info

Publication number
KR20240148351A
KR20240148351A KR1020247027226A KR20247027226A KR20240148351A KR 20240148351 A KR20240148351 A KR 20240148351A KR 1020247027226 A KR1020247027226 A KR 1020247027226A KR 20247027226 A KR20247027226 A KR 20247027226A KR 20240148351 A KR20240148351 A KR 20240148351A
Authority
KR
South Korea
Prior art keywords
compound
hours
solvent
contacting
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247027226A
Other languages
English (en)
Korean (ko)
Inventor
엥곡 덕 트란
크리스토스 시오우라스
에드워드 클레이터
윌리엄 마크 매턴
토마스 요아침 랜더왈드 람멜루
필리프 페르난데스
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20240148351A publication Critical patent/KR20240148351A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Health & Medical Sciences (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020247027226A 2022-02-18 2023-02-17 브루톤 티로신 키나제 억제제의 합성 Pending KR20240148351A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20220100151 2022-02-18
GR20220100151 2022-02-18
EP22167032 2022-04-06
EP22167032.6 2022-04-06
EP22178413.5 2022-06-10
EP22178413 2022-06-10
PCT/EP2023/054043 WO2023156599A1 (en) 2022-02-18 2023-02-17 Synthesis of bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20240148351A true KR20240148351A (ko) 2024-10-11

Family

ID=85227338

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247027226A Pending KR20240148351A (ko) 2022-02-18 2023-02-17 브루톤 티로신 키나제 억제제의 합성

Country Status (13)

Country Link
US (1) US20250163076A1 (https=)
EP (1) EP4479405A1 (https=)
JP (1) JP2025506671A (https=)
KR (1) KR20240148351A (https=)
AU (1) AU2023221549A1 (https=)
CA (1) CA3252338A1 (https=)
CL (1) CL2024002409A1 (https=)
CO (1) CO2024011229A2 (https=)
IL (1) IL314902A (https=)
JO (1) JOP20240182A1 (https=)
MX (1) MX2024010134A (https=)
PE (1) PE20242069A1 (https=)
WO (1) WO2023156599A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025262118A1 (en) * 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MX2024010134A (es) 2024-08-27
CA3252338A1 (en) 2023-08-24
EP4479405A1 (en) 2024-12-25
IL314902A (en) 2024-10-01
PE20242069A1 (es) 2024-10-18
JP2025506671A (ja) 2025-03-13
JOP20240182A1 (ar) 2024-08-14
CO2024011229A2 (es) 2024-08-30
US20250163076A1 (en) 2025-05-22
WO2023156599A1 (en) 2023-08-24
AU2023221549A1 (en) 2024-10-03
CL2024002409A1 (es) 2025-01-03

Similar Documents

Publication Publication Date Title
KR102693367B1 (ko) Ehmt2 저해제로서의 아민-치환된 헤테로사이클릭 화합물 및 이의 사용 방법
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
JP7797486B2 (ja) 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体
JP2023528394A (ja) 大環状ｊａｋ阻害剤およびその適用
EP3248980A1 (en) Jak inhibitor
WO2025053850A1 (en) Covalent kras-binding compounds for medical treatment
JP2016537369A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
AU2018389145A1 (en) Exo-aza spiro inhibitors of menin-MLL interaction
US20190152992A1 (en) Benzodioxane derivatives and their pharmaceutical use
KR20240148351A (ko) 브루톤 티로신 키나제 억제제의 합성
KR102412045B1 (ko) 혈액응고인자 Xa 억제제로서의 히드라지드 화합물
JP7068402B2 (ja) チアゾール誘導体の製造方法
BR112021001270A2 (pt) piridopirimidinas como inibidores do receptor h4 da histamina
CN111718332B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN116322692A (zh) 自分泌运动因子抑制剂化合物
CN118715228A (zh) 布鲁顿酪氨酸激酶抑制剂的合成
HK40111046A (zh) 布鲁顿酪氨酸激酶抑制剂的合成
AU2018393409A1 (en) Tetrahydropyrrole compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
EP3640250B1 (en) Compound as gls1 inhibitor
CN112500353A (zh) 一种左西孟旦的前药化合物、制备方法及其应用
CA3179593C (en) Pyridine derivative and application thereof
TW202508560A (zh) 製備ｐ１３ｋ抑制劑之方法
WO2017213210A1 (ja) 複素環化合物
CA3046864C (en) Cdk4/6 inhibitor
CN120787219A (zh) 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240813

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application